FINWIRES · TerminalLIVE
FINWIRES

Eisai, Merck's Phase 3 Kidney Cancer Drug Combo Trial Fails to Meet Survival Endpoints

By

-- Japanese pharmaceutical firm Eisai (TYO:4523) and U.S.-based Merck's experimental combination therapies failed to meet the dual primary endpoints of progression-free survival and overall survival in a Phase 3 trial.

The trial was evaluating first-line treatment for advanced clear cell renal cell carcinoma, a form of kidney cancer that accounts for approximately 80% of all cases, according to a joint statement on Tuesday.

The LITESPARK-012 study tested two regimens: Keytruda plus Lenvima plus Welireg, and MK-1308A (a co-formulation of Keytruda with an investigational antibody) plus Lenvima, against the established combination of Keytruda and Lenvima in 1,688 patients.

An interim analysis revealed that neither experimental combination met the study's two primary goals of improving overall survival and progression-free survival compared with the standard treatment.

Related Articles

Research

Research Alert: T-mobile Posts Industry-leading Q1 Results, Adds 217k Postpaid Accounts

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:T-Mobile reported Q1 2026 EPS of $2.27 vs $2.58 in Q1 2025, impacted by $476M UScellular merger costs and $105M transformation expenses, though service revenues grew 11% to $18.8B, with postpaid service revenue up 15% to $15.6B. Postpaid net account additions of 217k (+6% Y/Y) demonstrated continued market share gains despite earnings pressure from strategic investments. Industry-leading operational performance reflects network differentiation driving customer acquisition, with record switcher share citing network quality and fastest fixed wireless speeds. Management raised 2026 guidance for postpaid adds to 950K-1.05M, EBITDA to $37.1B-$37.5B, and FCF to $18.1B-$18.7B. Strong FCF of $4.6B enabled $6.0B stockholder returns, with Board increasing authorization to $18.2B from $14.6B. We expect continued profitable growth through network leadership, fiber expansion targeting 3M-4M customers by 2030, and scaling of T-Ads and T-Mobile Visa services.

$TMUS
Australia

Fair Isaac Fiscal Q2 Adjusted Earnings, Revenue Climb; FY Outlook Raised; Shares Gain After Hours

Fair Isaac (FICO) reported fiscal Q2 adjusted earnings late Tuesday of $12.50 per diluted share, up from $7.81 a year earlier.Analysts polled by FactSet expected $10.89.Revenue in the quarter ended March 31 rose to $691.7 million from $498.7 million a year earlier.Analysts surveyed by FactSet expected $630.2 million.The company raised fiscal 2026 guidance to adjusted EPS of $40.45 on revenue of $2.45 billion, compared with its prior forecast of EPS of $38.17 on revenue of $2.35 billion.Fair Isaac shares rose 5.9% in after-hours trading.

$FICO
Insider Trading

World Kinect Insider Sold Shares Worth $666,600, According to a Recent SEC Filing

Michael J Kasbar, Director, Executive Chairman, on April 24, 2026, sold 23,653 shares in World Kinect (WKC) for $666,600. Following the Form 4 filing with the SEC, Kasbar has control over a total of 1,062,797 common shares of the company, with 1,062,797 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/789460/000119312526187346/xslF345X05/ownership.xml

$WKC